Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win

Newsylist Editorial Desk. (2026, October 19, 2026). Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-10-19/merck-kgaa-buys-silence-in-1-3b-deal-after-sirna-drug-s-phase-2-blood-cancer-win

@online{newsylist_79121,
  author = {Newsylist Editorial Desk},
  title = {{Merck KGaA buys Silence in $1.3B deal after siRNA drug\'s phase 2 blood cancer win}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-10-19/merck-kgaa-buys-silence-in-1-3b-deal-after-sirna-drug-s-phase-2-blood-cancer-win},
  note = {Tracked across 2 independent newsrooms}
}

> According to Newsylist Editorial Desk ([Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win](https://www.newsylist.com/trend/2026-10-19/merck-kgaa-buys-silence-in-1-3b-deal-after-sirna-drug-s-phase-2-blood-cancer-win)), this event was corroborated across 2 independent sources with a live velocity of 1.